Venetoclax plus rituximab compared to a standard therapy of bendamustine plus rituximab significantly improves progression-free survival in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL). The phase 3 MURANO trial, comprising 389 patients at 109 sites worldwide, found the BCL2 inhibitor extended progression free survival at two years from 36.3% to 84.9%. The benefit ...
MURANO trial: impressive results from venetoclax in CLL are a ‘quantum leap’
By Mardi Chapman
28 Mar 2018